{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:17:36Z","timestamp":1794493056570,"version":"4.9.1"},"reference-count":214,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1038\/s41582-023-00918-8","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T08:02:04Z","timestamp":1705305724000},"page":"135-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Parkinson disease psychosis: from phenomenology to neurobiological mechanisms"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3248-704X","authenticated-orcid":false,"given":"Javier","family":"Pagonabarraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Bejr-Kasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul","family":"Martinez-Horta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4870-1431","authenticated-orcid":false,"given":"Jaime","family":"Kulisevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"918_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","volume":"13","author":"DH ffytche","year":"2017","unstructured":"ffytche, D. H. et al. The psychosis spectrum in Parkinson disease. Nat. Rev. Neurol. 13, 81\u201395 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"918_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nrneurol.2009.62","volume":"5","author":"NJ Diederich","year":"2009","unstructured":"Diederich, N. J., F\u00e9nelon, G., Stebbins, G. & Goetz, C. G. Hallucinations in Parkinson disease. Nat. Rev. Neurol. 5, 331\u2013342 (2009).","journal-title":"Nat. Rev. Neurol."},{"key":"918_CR3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1136\/jnnp.34.5.502","volume":"34","author":"AR Damasio","year":"1971","unstructured":"Damasio, A. R., Lobo-Antunes, J. & Macedo, C. Psychiatric aspects in Parkinsonism treated with L-dopa. J. Neurol. Neurosurg. Psychiatry 34, 502\u2013507 (1971).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"918_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1176\/ajp.135.6.669","volume":"135","author":"C Moskovitz","year":"1978","unstructured":"Moskovitz, C., Moses, H. 3rd & Klawans, H. L. Levodopa-induced psychosis: a kindling phenomenon. Am. J. Psychiatry 135, 669\u2013675 (1978).","journal-title":"Am. J. Psychiatry"},{"key":"918_CR5","first-page":"383","volume":"9","author":"UK Rinne","year":"1975","unstructured":"Rinne, U. K., Sonninen, V. & Marttila, R. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism. Adv. Neurol. 9, 383\u2013392 (1975).","journal-title":"Adv. Neurol."},{"key":"918_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/jnnp.39.2.184","volume":"39","author":"JD Parkes","year":"1976","unstructured":"Parkes, J. D. et al. Bromocriptine treatment in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 39, 184\u2013193 (1976).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"918_CR7","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1136\/jnnp.70.6.734","volume":"70","author":"S Holroyd","year":"2001","unstructured":"Holroyd, S. Prospective study of hallucinations and delusions in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 70, 734\u2013738 (2001).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"918_CR8","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1212\/WNL.57.11.2078","volume":"57","author":"CG Goetz","year":"2001","unstructured":"Goetz, C. G., Leurgans, S., Pappert, E. J., Raman, R. & Stemer, A. B. Prospective longitudinal assessment of hallucinations in Parkinson\u2019s disease. Neurology 57, 2078\u20132082 (2001).","journal-title":"Neurology"},{"key":"918_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1474-4422(05)70146-0","volume":"4","author":"DR Williams","year":"2005","unstructured":"Williams, D. R. & Lees, A. J. Visual hallucinations in the diagnosis of idiopathic Parkinson\u2019s disease: a retrospective autopsy study. Lancet Neurol. 4, 605\u2013610 (2005).","journal-title":"Lancet Neurol."},{"key":"918_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"G F\u00e9nelon","year":"2000","unstructured":"F\u00e9nelon, G. Hallucinations in Parkinson\u2019s disease: prevalence, phenomenology and risk factors. Brain 123, 733\u2013745 (2000).","journal-title":"Brain"},{"key":"918_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1212\/01.wnl.0000191325.31068.c4","volume":"66","author":"G F\u00e9nelon","year":"2006","unstructured":"F\u00e9nelon, G., Goetz, C. G. & Karenberg, A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology 66, 93\u201398 (2006).","journal-title":"Neurology"},{"key":"918_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/01.WNL.0000103444.45882.D8","volume":"62","author":"V Biousse","year":"2004","unstructured":"Biousse, V. et al. Ophthalmologic features of Parkinson\u2019s disease. Neurology 62, 177\u2013180 (2004).","journal-title":"Neurology"},{"key":"918_CR13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1136\/jnnp.2009.179655","volume":"81","author":"N Ibarretxe-Bilbao","year":"2010","unstructured":"Ibarretxe-Bilbao, N. et al. Differential progression of brain atrophy in Parkinson\u2019s disease with and without visual hallucinations. J. Neurol. Neurosurg. Psychiatry 81, 650\u2013657 (2010).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"918_CR14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/brain\/awt360","volume":"137","author":"JG Goldman","year":"2014","unstructured":"Goldman, J. G. et al. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson\u2019s disease with hallucinations. Brain 137, 849\u2013859 (2014).","journal-title":"Brain"},{"key":"918_CR15","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1093\/brain\/awp223","volume":"132","author":"AM Meppelink","year":"2009","unstructured":"Meppelink, A. M. et al. Impaired visual processing preceding image recognition in Parkinson\u2019s disease patients with visual hallucinations. Brain 132, 2980\u20132993 (2009).","journal-title":"Brain"},{"key":"918_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.parkreldis.2013.11.017","volume":"20","author":"J Pagonabarraga","year":"2014","unstructured":"Pagonabarraga, J. et al. Neural correlates of minor hallucinations in non-demented patients with Parkinson\u2019s disease. Parkinsonism Relat. Disord. 20, 290\u2013296 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"918_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1212\/WNL.0000000000007913","volume":"93","author":"A Lenka","year":"2019","unstructured":"Lenka, A., Pagonabarraga, J., Pal, P. K., Bejr-Kasem, H. & Kulisvesky, J. Minor hallucinations in Parkinson disease. Neurology 93, 259\u2013266 (2019).","journal-title":"Neurology"},{"key":"918_CR18","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/jnnp.2010.234799","volume":"82","author":"G F\u00e9nelon","year":"2011","unstructured":"F\u00e9nelon, G., Soulas, T., de Langavant, L. C., Trinkler, I. & Bachoud-Levi, A.-C. Feeling of presence in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 82, 1219\u20131224 (2011).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"918_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.26432","volume":"31","author":"J Pagonabarraga","year":"2016","unstructured":"Pagonabarraga, J. et al. Minor hallucinations occur in drug-naive Parkinson\u2019s disease patients, even from the premotor phase. Mov. Disord. 31, 45\u201352 (2016).","journal-title":"Mov. Disord."},{"key":"918_CR20","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/mds.21382","volume":"22","author":"B Ravina","year":"2007","unstructured":"Ravina, B. et al. Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an NINDS, NIMH work group. Mov. Disord. 22, 1061\u20131068 (2007).","journal-title":"Mov. Disord."},{"key":"918_CR21","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/mds.22839","volume":"25","author":"G F\u00e9nelon","year":"2010","unstructured":"F\u00e9nelon, G., Soulas, T., Zenasni, F. & de Langavant, L. C. The changing face of Parkinson\u2019s disease-associated psychosis: a cross-sectional study based on the new NINDS\u2013NIMH criteria. Mov. Disord. 25, 763\u2013766 (2010).","journal-title":"Mov. Disord."},{"key":"918_CR22","doi-asserted-by":"publisher","first-page":"3469706","DOI":"10.1155\/2021\/3469706","volume":"2021","author":"M Zhong","year":"2021","unstructured":"Zhong, M. et al. Prevalence and risk factors for minor hallucinations in patients with Parkinson\u2019s disease. Behav. Neurol. 2021, 3469706 (2021).","journal-title":"Behav. Neurol."},{"key":"918_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3389\/fneur.2015.00263","volume":"6","author":"RA Wood","year":"2015","unstructured":"Wood, R. A., Hopkins, S. A., Moodley, K. K. & Chan, D. Fifty percent prevalence of extracampine hallucinations in Parkinson\u2019s disease patients. Front. Neurol. 6, 263 (2015).","journal-title":"Front. Neurol."},{"key":"918_CR24","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/ene.14576","volume":"28","author":"H Bejr\u2010Kasem","year":"2021","unstructured":"Bejr\u2010Kasem, H. et al. Minor hallucinations reflect early gray matter loss and predict subjective cognitive decline in Parkinson\u2019s disease. Eur. J. Neurol. 28, 438\u2013447 (2021).","journal-title":"Eur. J. Neurol."},{"key":"918_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mds.20263","volume":"20","author":"A Do\u00e9 de Maindreville","year":"2005","unstructured":"Do\u00e9 de Maindreville, A., F\u00e9nelon, G. & Mahieux, F. Hallucinations in Parkinson\u2019s disease: a follow\u2010up study. Mov. Disord. 20, 212\u2013217 (2005).","journal-title":"Mov. Disord."},{"key":"918_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/psyg.12771","volume":"22","author":"C Sasaki","year":"2022","unstructured":"Sasaki, C. et al. Visual illusions in Parkinson\u2019s disease: an interview survey of symptomatology. Psychogeriatrics 22, 38\u201348 (2022).","journal-title":"Psychogeriatrics"},{"key":"918_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.parkreldis.2018.05.023","volume":"55","author":"Y Nishio","year":"2018","unstructured":"Nishio, Y. et al. Defining visual illusions in Parkinson\u2019s disease: kinetopsia and object misidentification illusions. Parkinsonism Relat. Disord. 55, 111\u2013116 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"918_CR28","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1002\/mds.22246","volume":"23","author":"J Kulisevsky","year":"2008","unstructured":"Kulisevsky, J., Pagonabarraga, J., Pascual-Sedano, B., Garc\u00eda-S\u00e1nchez, C. & Gironell, A. Prevalence and correlates of neuropsychiatric symptoms in Parkinson\u2019s disease without dementia. Mov. Disord. 23, 1889\u20131896 (2008).","journal-title":"Mov. Disord."},{"key":"918_CR29","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/gps.3869","volume":"28","author":"G Gibson","year":"2013","unstructured":"Gibson, G. et al. Frequency, prevalence, incidence and risk factors associated with visual hallucinations in a sample of patients with Parkinson\u2019s disease: a longitudinal 4-year study. Int. J. Geriatr. Psychiatry 28, 626\u2013631 (2013).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"918_CR30","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3233\/JPD-213035","volume":"12","author":"CD Stang","year":"2022","unstructured":"Stang, C. D. et al. Incidence, prevalence, and mortality of psychosis associated with Parkinson\u2019s disease (1991\u20132010). J. Parkinsons Dis. 12, 1319\u20131327 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"918_CR31","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/gps.389","volume":"16","author":"D Aarsland","year":"2001","unstructured":"Aarsland, D., Ballard, C., Larsen, J. P. & McKeith, I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson\u2019s disease with and without dementia. Int. J. Geriatr. Psychiatry 16, 528\u2013536 (2001).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"918_CR32","first-page":"100119","volume":"5","author":"I Chendo","year":"2021","unstructured":"Chendo, I. et al. High frequency of psychosis in late-stage Parkinson\u2019s disease. Clin. Park. Relat. Disord. 5, 100119 (2021).","journal-title":"Clin. Park. Relat. Disord."},{"key":"918_CR33","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/archneurol.2010.166","volume":"67","author":"EB Forsaa","year":"2010","unstructured":"Forsaa, E. B. et al. A 12-year population-based study of psychosis in Parkinson disease. Arch. Neurol. 67, 996\u20131001 (2010).","journal-title":"Arch. Neurol."},{"key":"918_CR34","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1136\/jnnp-2019-322702","volume":"91","author":"J O\u2019Brien","year":"2020","unstructured":"O\u2019Brien, J. et al. Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. J. Neurol. Neurosurg. Psychiatry 91, 512\u2013519 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"918_CR35","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1212\/WNL.45.4.669","volume":"45","author":"CG Goetz","year":"1995","unstructured":"Goetz, C. G. & Stebbins, G. T. Mortality and hallucinations in nursing home patients with advanced Parkinson\u2019s disease. Neurology 45, 669\u2013671 (1995).","journal-title":"Neurology"},{"key":"918_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/13546805.2021.1960812","volume":"27","author":"M Montagnese","year":"2022","unstructured":"Montagnese, M. et al. Cognition, hallucination severity and hallucination-specific insight in neurodegenerative disorders and eye disease. Cogn. Neuropsychiatry 27, 105\u2013121 (2022).","journal-title":"Cogn. Neuropsychiatry"},{"key":"918_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/01.JGP.0000192480.89813.80","volume":"14","author":"UP Mosimann","year":"2006","unstructured":"Mosimann, U. P. et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with Lewy bodies. Am. J. Geriatr. Psychiatry 14, 153\u2013160 (2006).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"918_CR38","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1586\/14737175.7.12.1731","volume":"7","author":"M Onofrj","year":"2007","unstructured":"Onofrj, M., Thomas, A. & Bonanni, L. New approaches to understanding hallucinations in Parkinson\u2019s disease: phenomenology and possible origins. Expert Rev. Neurother. 7, 1731\u20131750 (2007).","journal-title":"Expert Rev. Neurother."},{"key":"918_CR39","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1017\/S0033291718003161","volume":"49","author":"CL Eversfield","year":"2019","unstructured":"Eversfield, C. L. & Orton, L. D. Auditory and visual hallucination prevalence in Parkinson\u2019s disease and dementia with Lewy bodies: a systematic review and meta-analysis. Psychol. Med. 49, 2342\u20132353 (2019).","journal-title":"Psychol. Med."},{"key":"918_CR40","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00415-002-0908-9","volume":"249","author":"G F\u00e9nelon","year":"2002","unstructured":"F\u00e9nelon, G., Thobois, S., Bonnet, A.-M., Broussolle, E. & Tison, F. Tactile hallucinations in Parkinson\u2019s disease. J. Neurol. 249, 1699\u20131703 (2002).","journal-title":"J. Neurol."},{"key":"918_CR41","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1212\/WNL.51.3.811","volume":"51","author":"CG Goetz","year":"1998","unstructured":"Goetz, C. G., Vogel, C., Tanner, C. M. & Stebbins, G. T. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 51, 811\u2013814 (1998).","journal-title":"Neurology"},{"key":"918_CR42","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1002\/mds.23835","volume":"26","author":"CG Goetz","year":"2011","unstructured":"Goetz, C. G., Stebbins, G. T. & Ouyang, B. Visual plus nonvisual hallucinations in Parkinson\u2019s disease: development and evolution over 10 years. Mov. Disord. 26, 2196\u20132200 (2011).","journal-title":"Mov. Disord."},{"key":"918_CR43","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association Publishing, 2022).","DOI":"10.1176\/appi.books.9780890425787"},{"key":"918_CR44","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jns.2014.10.033","volume":"347","author":"SA Factor","year":"2014","unstructured":"Factor, S. A. et al. Cognitive correlates of hallucinations and delusions in Parkinson\u2019s disease. J. Neurol. Sci. 347, 316\u2013321 (2014).","journal-title":"J. Neurol. Sci."},{"key":"918_CR45","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11065-018-9379-3","volume":"28","author":"N Warren","year":"2018","unstructured":"Warren, N., O\u2019Gorman, C., Hume, Z., Kisely, S. & Siskind, D. Delusions in Parkinson\u2019s disease: a systematic review of published cases. Neuropsychol. Rev. 28, 310\u2013316 (2018).","journal-title":"Neuropsychol. Rev."},{"key":"918_CR46","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.parkreldis.2010.06.010","volume":"16","author":"N Stefanis","year":"2010","unstructured":"Stefanis, N. et al. Isolated delusional syndrome in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 16, 550\u2013552 (2010).","journal-title":"Parkinsonism Relat. Disord."},{"key":"918_CR47","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s00415-006-0388-4","volume":"254","author":"G Kiziltan","year":"2007","unstructured":"Kiziltan, G., \u00d6zekmek\u00e7i, S., Ertan, S., Ertan, T. & Ergin\u00f6z, E. Relationship between age and subtypes of psychotic symptoms in Parkinson\u2019s disease. J. Neurol. 254, 448\u2013452 (2007).","journal-title":"J. Neurol."},{"key":"918_CR48","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/mds.25129","volume":"27","author":"M Poletti","year":"2012","unstructured":"Poletti, M. et al. Dopamine agonists and delusional jealousy in Parkinson\u2019s disease: a cross-sectional prevalence study. Mov. Disord. 27, 1679\u20131682 (2012).","journal-title":"Mov. Disord."},{"key":"918_CR49","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s10072-021-05249-4","volume":"42","author":"G De Michele","year":"2021","unstructured":"De Michele, G. et al. Othello syndrome in Parkinson\u2019s disease: a systematic review and report of a case series. Neurol. Sci. 42, 2721\u20132729 (2021).","journal-title":"Neurol. Sci."},{"key":"918_CR50","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4088\/JCP.14m09018","volume":"76","author":"M Hashimoto","year":"2015","unstructured":"Hashimoto, M., Sakamoto, S. & Ikeda, M. Clinical features of delusional jealousy in elderly patients with dementia. J. Clin. Psychiatry 76, 691\u2013695 (2015).","journal-title":"J. Clin. Psychiatry"},{"key":"918_CR51","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1176\/ajp.156.7.1039","volume":"156","author":"C Ballard","year":"1999","unstructured":"Ballard, C. et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer\u2019s disease. Am. J. Psychiatry 156, 1039\u20131045 (1999).","journal-title":"Am. J. Psychiatry"},{"key":"918_CR52","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/WAD.0000000000000141","volume":"30","author":"G Perini","year":"2016","unstructured":"Perini, G. et al. Misidentification delusions. Alzheimer Dis. Assoc. Disord. 30, 331\u2013337 (2016).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"918_CR53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11920-009-0029-6","volume":"11","author":"GN Christodoulou","year":"2009","unstructured":"Christodoulou, G. N., Margariti, M., Kontaxakis, V. P. & Christodoulou, N. G. The delusional misidentification syndromes: strange, fascinating, and instructive. Curr. Psychiatry Rep. 11, 185\u2013189 (2009).","journal-title":"Curr. Psychiatry Rep."},{"key":"918_CR54","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/mds.21864","volume":"23","author":"J Pagonabarraga","year":"2008","unstructured":"Pagonabarraga, J. et al. A prospective study of delusional misidentification syndromes in Parkinson\u2019s disease with dementia. Mov. Disord. 23, 443\u2013448 (2008).","journal-title":"Mov. Disord."},{"key":"918_CR55","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1176\/jnp.10.2.194","volume":"10","author":"DM Roane","year":"1998","unstructured":"Roane, D. M., Rogers, J. D., Robinson, J. H. & Feinberg, T. E. Delusional misidentification in association with parkinsonism. J. Neuropsychiatry Clin. Neurosci. 10, 194\u2013198 (1998).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"918_CR56","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1080\/00325481.2018.1411161","volume":"130","author":"N Hermanowicz","year":"2018","unstructured":"Hermanowicz, N. Delusional misidentification in Parkinson\u2019s disease: report of two cases and a review. Postgrad. Med. 130, 280\u2013283 (2018).","journal-title":"Postgrad. Med."},{"key":"918_CR57","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.parkreldis.2013.04.021","volume":"19","author":"A Moro","year":"2013","unstructured":"Moro, A., Munhoz, R. P., Moscovich, M., Arruda, W. O. & Teive, H. A. G. Delusional misidentification syndrome and other unusual delusions in advanced Parkinson\u2019s disease. Parkinsonism Relat. Disord. 19, 751\u2013754 (2013).","journal-title":"Parkinsonism Relat. Disord."},{"key":"918_CR58","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/brain\/awp295","volume":"133","author":"Y Nagahama","year":"2010","unstructured":"Nagahama, Y., Okina, T., Suzuki, N. & Matsuda, M. Neural correlates of psychotic symptoms in dementia with Lewy bodies. Brain 133, 557\u2013567 (2010).","journal-title":"Brain"},{"key":"918_CR59","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/0006-3223(94)00326-X","volume":"38","author":"MJ Mentis","year":"1995","unstructured":"Mentis, M. J. et al. Abnormal brain glucose metabolism in the delusional misidentification syndromes: a positron emission tomography study in Alzheimer disease. Biol. Psychiatry 38, 438\u2013449 (1995).","journal-title":"Biol. Psychiatry"},{"key":"918_CR60","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1523\/JNEUROSCI.2901-17.2018","volume":"38","author":"VA Weilnhammer","year":"2018","unstructured":"Weilnhammer, V. A., Stuke, H., Sterzer, P. & Schmack, K. The neural correlates of hierarchical predictions for perceptual decisions. J. Neurosci. 38, 5008\u20135021 (2018).","journal-title":"J. Neurosci."},{"key":"918_CR61","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.neubiorev.2021.06.030","volume":"128","author":"S Pezzoli","year":"2021","unstructured":"Pezzoli, S. et al. Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson\u2019s disease and dementia with Lewy bodies: voxel-based morphometry and neuropsychological meta-analysis. Neurosci. Biobehav. Rev. 128, 367\u2013382 (2021).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"918_CR62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"D Aarsland","year":"2021","unstructured":"Aarsland, D. et al. Parkinson disease-associated cognitive impairment. Nat. Rev. Dis. Primers 7, 47 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"918_CR63","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00702-019-02003-1","volume":"126","author":"S Martinez-Horta","year":"2019","unstructured":"Martinez-Horta, S. & Kulisevsky, J. Mild cognitive impairment in Parkinson\u2019s disease. J. Neural Transm. 126, 897\u2013904 (2019).","journal-title":"J. Neural Transm."},{"key":"918_CR64","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.0000000000000842","volume":"83","author":"JB Anang","year":"2014","unstructured":"Anang, J. B. et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 83, 1253\u20131260 (2014).","journal-title":"Neurology"},{"key":"918_CR65","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/archneur.63.5.713","volume":"63","author":"CG Goetz","year":"2006","unstructured":"Goetz, C. G., Fan, W., Leurgans, S., Bernard, B. & Stebbins, G. T. The malignant course of \u201cbenign hallucinations\u201d in Parkinson disease. Arch. Neurol. 63, 713\u2013716 (2006).","journal-title":"Arch. Neurol."},{"key":"918_CR66","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/mds.23411","volume":"25","author":"G Llebaria","year":"2010","unstructured":"Llebaria, G. et al. Neuropsychological correlates of mild to severe hallucinations in Parkinson\u2019s disease. Mov. Disord. 25, 2785\u20132791 (2010).","journal-title":"Mov. Disord."},{"key":"918_CR67","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/mds.23525","volume":"26","author":"K Bronnick","year":"2011","unstructured":"Bronnick, K., Emre, M., Tekin, S., Haugen, S. B. & Aarsland, D. Cognitive correlates of visual hallucinations in dementia associated with Parkinson\u2019s disease. Mov. Disord. 26, 824\u2013829 (2011).","journal-title":"Mov. Disord."},{"key":"918_CR68","doi-asserted-by":"publisher","first-page":"fcac329","DOI":"10.1093\/braincomms\/fcac329","volume":"5","author":"GEC Thomas","year":"2023","unstructured":"Thomas, G. E. C. et al. Changes in both top-down and bottom-up effective connectivity drive visual hallucinations in Parkinson\u2019s disease. Brain Commun. 5, fcac329 (2023).","journal-title":"Brain Commun."},{"key":"918_CR69","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1073\/pnas.0700622104","volume":"104","author":"T Serre","year":"2007","unstructured":"Serre, T., Oliva, A. & Poggio, T. A feedforward architecture accounts for rapid categorization. Proc. Natl Acad. Sci. USA 104, 6424\u20136429 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"918_CR70","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nrn3292","volume":"13","author":"O Blanke","year":"2012","unstructured":"Blanke, O. Multisensory brain mechanisms of bodily self-consciousness. Nat. Rev. Neurosci. 13, 556\u2013571 (2012).","journal-title":"Nat. Rev. Neurosci."},{"key":"918_CR71","doi-asserted-by":"publisher","first-page":"eabc8362","DOI":"10.1126\/scitranslmed.abc8362","volume":"13","author":"F Bernasconi","year":"2021","unstructured":"Bernasconi, F. et al. Robot-induced hallucinations in Parkinson\u2019s disease depend on altered sensorimotor processing in fronto-temporal network. Sci. Transl. Med. 13, eabc8362 (2021).","journal-title":"Sci. Transl. Med."},{"key":"918_CR72","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1162\/089892903321662976","volume":"15","author":"M Bar","year":"2003","unstructured":"Bar, M. A cortical mechanism for triggering top-down facilitation in visual object recognition. J. Cogn. Neurosci. 15, 600\u2013609 (2003).","journal-title":"J. Cogn. Neurosci."},{"key":"918_CR73","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1017\/S0140525X05000130","volume":"28","author":"D Collerton","year":"2005","unstructured":"Collerton, D., Perry, E. & McKeith, I. Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations. Behav. Brain Sci. 28, 737\u2013757 (2005).","journal-title":"Behav. Brain Sci."},{"key":"918_CR74","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/hbm.22321","volume":"35","author":"JM Shine","year":"2014","unstructured":"Shine, J. M. et al. The role of dysfunctional attentional control networks in visual misperceptions in Parkinson\u2019s disease. Hum. Brain Mapp. 35, 2206\u20132219 (2014).","journal-title":"Hum. Brain Mapp."},{"key":"918_CR75","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3389\/fpsyg.2015.01289","volume":"6","author":"HE Schendan","year":"2015","unstructured":"Schendan, H. E. & Ganis, G. Top-down modulation of visual processing and knowledge after 250\u2009ms supports object constancy of category decisions. Front. Psychol. 6, 1289 (2015).","journal-title":"Front. Psychol."},{"key":"918_CR76","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.neuroimage.2008.09.061","volume":"44","author":"HE Schendan","year":"2009","unstructured":"Schendan, H. E. & Maher, S. M. Object knowledge during entry-level categorization is activated and modified by implicit memory after 200\u2009ms. Neuroimage 44, 1423\u20131438 (2009).","journal-title":"Neuroimage"},{"key":"918_CR77","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.parkreldis.2022.07.009","volume":"102","author":"H Bejr-Kasem","year":"2022","unstructured":"Bejr-Kasem, H. et al. The role of attentional control over interference in minor hallucinations in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 102, 101\u2013107 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"key":"918_CR78","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0028-3932(02)00182-3","volume":"41","author":"J Barnes","year":"2003","unstructured":"Barnes, J., Boubert, L., Harris, J., Lee, A. & David, A. S. Reality monitoring and visual hallucinations in Parkinson\u2019s disease. Neuropsychologia 41, 565\u2013574 (2003).","journal-title":"Neuropsychologia"},{"key":"918_CR79","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1037\/0033-2909.114.1.3","volume":"114","author":"MK Johnson","year":"1993","unstructured":"Johnson, M. K., Hashtroudi, S. & Lindsay, D. S. Source monitoring. Psychol. Bull. 114, 3\u201328 (1993).","journal-title":"Psychol. Bull."},{"key":"918_CR80","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26004","volume":"29","author":"AJ Muller","year":"2014","unstructured":"Muller, A. J., Shine, J. M., Halliday, G. M. & Lewis, S. J. G. Visual hallucinations in Parkinson\u2019s disease: theoretical models. Mov. Disord. 29, 1591\u20131598 (2014).","journal-title":"Mov. Disord."},{"key":"918_CR81","doi-asserted-by":"publisher","first-page":"105208","DOI":"10.1016\/j.neubiorev.2023.105208","volume":"150","author":"D Collerton","year":"2023","unstructured":"Collerton, D. et al. Understanding visual hallucinations: a new synthesis. Neurosci. Biobehav. Rev. 150, 105208 (2023).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"918_CR82","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cortex.2015.10.015","volume":"74","author":"MR Geddes","year":"2016","unstructured":"Geddes, M. R. et al. Altered functional connectivity in lesional peduncular hallucinosis with REM sleep behavior disorder. Cortex 74, 96\u2013106 (2016).","journal-title":"Cortex"},{"key":"918_CR83","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/jnnp-2017-315741","volume":"88","author":"Y Nishio","year":"2017","unstructured":"Nishio, Y. et al. Deconstructing psychosis and misperception symptoms in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 88, 722\u2013729 (2017).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"918_CR84","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/mds.27557","volume":"34","author":"H Bejr-Kasem","year":"2019","unstructured":"Bejr-Kasem, H. et al. Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson\u2019s disease. Mov. Disord. 34, 78\u201386 (2019).","journal-title":"Mov. Disord."},{"key":"918_CR85","doi-asserted-by":"publisher","first-page":"923560","DOI":"10.3389\/fnagi.2022.923560","volume":"14","author":"M Zhong","year":"2022","unstructured":"Zhong, M. et al. Aberrant gray matter volume and functional connectivity in Parkinson\u2019s disease with minor hallucination. Front. Aging Neurosci. 14, 923560 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"918_CR86","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1097\/JGP.0b013e3180cc1fdf","volume":"15","author":"Y Nagahama","year":"2007","unstructured":"Nagahama, Y. et al. Classification of psychotic symptoms in dementia with Lewy bodies. Am. J. Geriatr. Psychiatry 15, 961\u2013967 (2007).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"918_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28087-0","volume":"13","author":"M Vignando","year":"2022","unstructured":"Vignando, M. et al. Mapping brain structural differences and neuroreceptor correlates in Parkinson\u2019s disease visual hallucinations. Nat. Commun. 13, 519 (2022).","journal-title":"Nat. Commun."},{"key":"918_CR88","doi-asserted-by":"publisher","first-page":"e1618","DOI":"10.1212\/WNL.0000000000005421","volume":"90","author":"MJ Barrett","year":"2018","unstructured":"Barrett, M. J., Blair, J. C., Sperling, S. A., Smolkin, M. E. & Druzgal, T. J. Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease. Neurology 90, e1618\u2013e1626 (2018).","journal-title":"Neurology"},{"key":"918_CR89","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00702-018-1891-3","volume":"125","author":"A Lenka","year":"2018","unstructured":"Lenka, A. et al. Hippocampal subfield atrophy in patients with Parkinson\u2019s disease and psychosis. J. Neural Transm. 125, 1361\u20131372 (2018).","journal-title":"J. Neural Transm."},{"key":"918_CR90","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/j.1468-1331.2007.01768.x","volume":"14","author":"B Ram\u00edrez-Ruiz","year":"2007","unstructured":"Ram\u00edrez-Ruiz, B. et al. Cerebral atrophy in Parkinson\u2019s disease patients with visual hallucinations. Eur. J. Neurol. 14, 750\u2013756 (2007).","journal-title":"Eur. J. Neurol."},{"key":"918_CR91","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1136\/jnnp-2012-303391","volume":"83","author":"S Shin","year":"2012","unstructured":"Shin, S. et al. Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 83, 1155\u20131161 (2012).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"918_CR92","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/mds.25641","volume":"28","author":"H Watanabe","year":"2013","unstructured":"Watanabe, H. et al. Cortical and subcortical brain atrophy in Parkinson\u2019s disease with visual hallucination. Mov. Disord. 28, 1732\u20131736 (2013).","journal-title":"Mov. Disord."},{"key":"918_CR93","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s004150050364","volume":"246","author":"K Okada","year":"1999","unstructured":"Okada, K., Suyama, N., Oguro, H., Yamaguchi, S. & Kobayashi, S. Medication-induced hallucination and cerebral blood flow in Parkinson\u2019s disease. J. Neurol. 246, 365\u2013368 (1999).","journal-title":"J. Neurol."},{"key":"918_CR94","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1212\/01.WNL.0000141853.27081.BD","volume":"63","author":"GT Stebbins","year":"2004","unstructured":"Stebbins, G. T. et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 63, 1409\u20131416 (2004).","journal-title":"Neurology"},{"key":"918_CR95","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1212\/01.wnl.0000187116.13370.e0","volume":"65","author":"N Oishi","year":"2011","unstructured":"Oishi, N. et al. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 65, 1708\u20131715 (2011).","journal-title":"Neurology"},{"key":"918_CR96","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1002\/mds.21140","volume":"21","author":"H Matsui","year":"2006","unstructured":"Matsui, H. et al. Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations. Mov. Disord. 21, 2140\u20132144 (2006).","journal-title":"Mov. Disord."},{"key":"918_CR97","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/archneur.64.7.984","volume":"64","author":"H Boecker","year":"2015","unstructured":"Boecker, H., Ceballos-Baumann, A. O., Volk, D. & Conrad, B. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch. Neurol. 64, 984\u2013988 (2015).","journal-title":"Arch. Neurol."},{"key":"918_CR98","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/mds.25554","volume":"29","author":"CG Goetz","year":"2014","unstructured":"Goetz, C. G., Vaughan, C. L., Goldman, J. G. & Stebbins, G. T. I finally see what you see: Parkinson\u2019s disease visual hallucinations captured with functional neuroimaging. Mov. Disord. 29, 115\u2013117 (2014).","journal-title":"Mov. Disord."},{"key":"918_CR99","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/hbm.23080","volume":"37","author":"C Gasca-Salas","year":"2016","unstructured":"Gasca-Salas, C., Clavero, P., Garc\u00eda-Garc\u00eda, D., Obeso, J. A. & Rodr\u00edguez-Oroz, M. C. Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson\u2019s disease patients with mild cognitive impairment. Hum. Brain Mapp. 37, 968\u2013977 (2016).","journal-title":"Hum. Brain Mapp."},{"key":"918_CR100","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/mds.20965","volume":"21","author":"B Ram\u00edrez-Ruiz","year":"2006","unstructured":"Ram\u00edrez-Ruiz, B., Junqu\u00e9, C., Mart\u00ed, M.-J., Valldeoriola, F. & Tolosa, E. Neuropsychological deficits in Parkinson\u2019s disease patients with visual hallucinations. Mov. Disord. 21, 1483\u20131487 (2006).","journal-title":"Mov. Disord."},{"key":"918_CR101","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/mds.20129","volume":"19","author":"A Nagano-Saito","year":"2004","unstructured":"Nagano-Saito, A. et al. Visual hallucination in Parkinson\u2019s disease with FDG PET. Mov. Disord. 19, 801\u2013806 (2004).","journal-title":"Mov. Disord."},{"key":"918_CR102","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1002\/mds.22258","volume":"23","author":"B Ramirez-Ruiz","year":"2008","unstructured":"Ramirez-Ruiz, B. et al. Brain response to complex visual stimuli in Parkinson\u2019s patients with hallucinations: a functional magnetic resonance imaging study. Mov. Disord. 23, 2335\u20132343 (2008).","journal-title":"Mov. Disord."},{"key":"918_CR103","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/mds.22873","volume":"25","author":"C Sanchez-Castaneda","year":"2010","unstructured":"Sanchez-Castaneda, C. et al. Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson\u2019s disease with dementia. Mov. Disord. 25, 615\u2013622 (2010).","journal-title":"Mov. Disord."},{"key":"918_CR104","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bandc.2014.03.011","volume":"87","author":"RL Gama","year":"2014","unstructured":"Gama, R. L. et al. Structural brain abnormalities in patients with Parkinson\u2019s disease with visual hallucinations: a comparative voxel-based analysis. Brain Cogn. 87, 97\u2013103 (2014).","journal-title":"Brain Cogn."},{"key":"918_CR105","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00415-008-0885-8","volume":"255","author":"N Ibarretxe-Bilbao","year":"2008","unstructured":"Ibarretxe-Bilbao, N. et al. Hippocampal head atrophy predominance in Parkinson\u2019s disease with hallucinations and with dementia. J. Neurol. 255, 1324\u20131331 (2008).","journal-title":"J. Neurol."},{"key":"918_CR106","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00415-011-6149-z","volume":"259","author":"J Janzen","year":"2012","unstructured":"Janzen, J. et al. The pedunculopontine nucleus is related to visual hallucinations in Parkinson\u2019s disease: preliminary results of a voxel-based morphometry study. J. Neurol. 259, 147\u2013154 (2012).","journal-title":"J. Neurol."},{"key":"918_CR107","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1002\/mds.23896","volume":"26","author":"JM Shine","year":"2011","unstructured":"Shine, J. M., Halliday, G. M., Naismith, S. L. & Lewis, S. J. G. Visual misperceptions and hallucinations in Parkinson\u2019s disease: dysfunction of attentional control networks? Mov. Disord. 26, 2154\u20132159 (2011).","journal-title":"Mov. Disord."},{"key":"918_CR108","first-page":"20142047","volume":"282","author":"JM Shine","year":"2015","unstructured":"Shine, J. M. et al. Imagine that: elevated sensory strength of mental imagery in individuals with Parkinson\u2019s disease and visual hallucinations. Proc. Biol. Sci. 282, 20142047 (2015).","journal-title":"Proc. Biol. Sci."},{"key":"918_CR109","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1038\/npjparkd.2015.3","volume":"1","author":"JM Shine","year":"2015","unstructured":"Shine, J. M. et al. Abnormal connectivity between the default mode and the visual system underlies the manifestation of visual hallucinations in Parkinson\u2019s disease: a task-based fMRI study. Parkinsons Dis. 1, 15003 (2015).","journal-title":"Parkinsons Dis."},{"key":"918_CR110","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nrn755","volume":"3","author":"M Corbetta","year":"2002","unstructured":"Corbetta, M. & Shulman, G. L. Control of goal-directed and stimulus-driven attention in the brain. Nat. Rev. Neurosci. 3, 201\u2013215 (2002).","journal-title":"Nat. Rev. Neurosci."},{"key":"918_CR111","doi-asserted-by":"publisher","first-page":"9673","DOI":"10.1073\/pnas.0504136102","volume":"102","author":"MD Fox","year":"2005","unstructured":"Fox, M. D. et al. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc. Natl Acad. Sci. USA 102, 9673\u20139678 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"918_CR112","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41583-019-0212-7","volume":"20","author":"RL Buckner","year":"2019","unstructured":"Buckner, R. L. & DiNicola, L. M. The brain\u2019s default network: updated anatomy, physiology and evolving insights. Nat. Rev. Neurosci. 20, 593\u2013608 (2019).","journal-title":"Nat. Rev. Neurosci."},{"key":"918_CR113","first-page":"194","volume":"26","author":"GJ Lewis","year":"2013","unstructured":"Lewis, G. J. & Bates, T. C. The long reach of the gene. Psychologist 26, 194\u2013198 (2013).","journal-title":"Psychologist"},{"key":"918_CR114","doi-asserted-by":"publisher","first-page":"10046","DOI":"10.1073\/pnas.0604187103","volume":"103","author":"MD Fox","year":"2006","unstructured":"Fox, M. D., Corbetta, M., Snyder, A. Z., Vincent, J. L. & Raichle, M. E. Spontaneous neuronal activity distinguishes human dorsal and ventral attention systems. Proc. Natl Acad. Sci. USA 103, 10046\u201310051 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"918_CR115","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/hbm.20688","volume":"30","author":"MA Eckert","year":"2009","unstructured":"Eckert, M. A. et al. At the heart of the ventral attention system: the right anterior insula. Hum. Brain Mapp. 30, 2530\u20132541 (2009).","journal-title":"Hum. Brain Mapp."},{"key":"918_CR116","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.24900","volume":"27","author":"JM Shine","year":"2012","unstructured":"Shine, J. M., Halliday, G. H., Carlos, M., Naismith, S. L. & Lewis, S. J. G. Investigating visual misperceptions in Parkinson\u2019s disease: a novel behavioral paradigm. Mov. Disord. 27, 500\u2013505 (2012).","journal-title":"Mov. Disord."},{"key":"918_CR117","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1148\/radiol.2017170438","volume":"285","author":"DH Hepp","year":"2017","unstructured":"Hepp, D. H. et al. Loss of functional connectivity in patients with Parkinson disease and visual hallucinations. Radiology 285, 896\u2013903 (2017).","journal-title":"Radiology"},{"key":"918_CR118","doi-asserted-by":"publisher","first-page":"102076","DOI":"10.1016\/j.nicl.2019.102076","volume":"25","author":"K Miloserdov","year":"2020","unstructured":"Miloserdov, K. et al. Aberrant functional connectivity of resting state networks related to misperceptions and intra-individual variability in Parkinson\u2019s disease. Neuroimage Clin. 25, 102076 (2020).","journal-title":"Neuroimage Clin."},{"key":"918_CR119","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11682-019-00185-6","volume":"14","author":"K Dujardin","year":"2020","unstructured":"Dujardin, K. et al. What can we learn from fMRI capture of visual hallucinations in Parkinson\u2019s disease? Brain Imaging Behav. 14, 329\u2013335 (2020).","journal-title":"Brain Imaging Behav."},{"key":"918_CR120","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.cortex.2019.12.023","volume":"125","author":"IC Walpola","year":"2020","unstructured":"Walpola, I. C. et al. Mind-wandering in Parkinson\u2019s disease hallucinations reflects primary visual and default network coupling. Cortex 125, 233\u2013245 (2020).","journal-title":"Cortex"},{"key":"918_CR121","doi-asserted-by":"publisher","first-page":"10227","DOI":"10.1016\/j.nicl.2020.102277","volume":"27","author":"F Knolle","year":"2020","unstructured":"Knolle, F. et al. Altered subcortical emotional salience processing differentiates Parkinson\u2019s patients with and without psychotic symptoms. Neuroimage Clin. 27, 10227 (2020).","journal-title":"Neuroimage Clin."},{"key":"918_CR122","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s42003-022-03903-x","volume":"5","author":"A Zarkali","year":"2022","unstructured":"Zarkali, A. et al. Changes in dynamic transitions between integrated and segregated states underlie visual hallucinations in Parkinson\u2019s disease. Commun. Biol. 5, 928 (2022).","journal-title":"Commun. Biol."},{"key":"918_CR123","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/mds.27781","volume":"34","author":"M Onofrj","year":"2019","unstructured":"Onofrj, M., Espay, A. J., Bonanni, L., Delli Pizzi, S. & Sensi, S. L. Hallucinations, somatic\u2010functional disorders of PD\u2010DLB as expressions of thalamic dysfunction. Mov. Disord. 34, 1100\u20131111 (2019).","journal-title":"Mov. Disord."},{"key":"918_CR124","doi-asserted-by":"publisher","first-page":"E1525","DOI":"10.1212\/WNL.0000000000009014","volume":"94","author":"A Zarkali","year":"2020","unstructured":"Zarkali, A. et al. Fiber-specific white matter reductions in Parkinson hallucinations and visual dysfunction. Neurology 94, E1525\u2013E1538 (2020).","journal-title":"Neurology"},{"key":"918_CR125","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/jnnp-2021-326630","volume":"93","author":"A Zarkali","year":"2022","unstructured":"Zarkali, A., McColgan, P., Leyland, L. A., Lees, A. J. & Weil, R. S. Longitudinal thalamic white and grey matter changes associated with visual hallucinations in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 93, 169\u2013179 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"918_CR126","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1093\/brain\/awaa270","volume":"143","author":"A Zarkali","year":"2021","unstructured":"Zarkali, A. et al. Differences in network controllability and regional gene expression underlie hallucinations in Parkinson\u2019s disease. Brain 143, 3435\u20133448 (2021).","journal-title":"Brain"},{"key":"918_CR127","doi-asserted-by":"publisher","first-page":"fcac329","DOI":"10.1093\/braincomms\/fcac329","volume":"5","author":"GEC Thomas","year":"2022","unstructured":"Thomas, G. E. C. et al. Changes in both top-down and bottom-up effective connectivity drive visual hallucinations in Parkinson\u2019s disease. Brain Commun. 5, fcac329 (2022).","journal-title":"Brain Commun."},{"key":"918_CR128","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1093\/cercor\/bht146","volume":"24","author":"M Chaumon","year":"2014","unstructured":"Chaumon, M., Kveraga, K., Barrett, L. F. & Bar, M. Visual predictions in the orbitofrontal cortex rely on associative content. Cereb. Cortex 24, 2899\u20132907 (2014).","journal-title":"Cereb. Cortex"},{"key":"918_CR129","doi-asserted-by":"publisher","first-page":"fcz007","DOI":"10.1093\/braincomms\/fcz007","volume":"1","author":"A Zarkali","year":"2019","unstructured":"Zarkali, A. et al. Increased weighting on prior knowledge in Lewy body-associated visual hallucinations. Brain Commun. 1, fcz007 (2019).","journal-title":"Brain Commun."},{"key":"918_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/srep36284","volume":"6","author":"S Lefebvre","year":"2016","unstructured":"Lefebvre, S. et al. Hallucinations and conscious access to visual inputs in Parkinson\u2019s disease. Sci. Rep. 6, 36284 (2016).","journal-title":"Sci. Rep."},{"key":"918_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50106-2","volume":"9","author":"A Perinelli","year":"2019","unstructured":"Perinelli, A., Tabarelli, D., Miniussi, C. & Ricci, L. Dependence of connectivity on geometric distance in brain networks. Sci. Rep. 9, 13412 (2019).","journal-title":"Sci. Rep."},{"key":"918_CR132","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.1002\/hbm.22577","volume":"35","author":"N Yao","year":"2014","unstructured":"Yao, N. et al. The default mode network is disrupted in parkinson\u2019s disease with visual hallucinations. Hum. Brain Mapp. 35, 5658\u20135666 (2014).","journal-title":"Hum. Brain Mapp."},{"key":"918_CR133","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/mds.26285","volume":"30","author":"R Franciotti","year":"2015","unstructured":"Franciotti, R. et al. Default mode network links to visual hallucinations: a comparison between Parkinson\u2019s disease and multiple system atrophy. Mov. Disord. 30, 1237\u20131247 (2015).","journal-title":"Mov. Disord."},{"key":"918_CR134","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00429-014-0907-5","volume":"221","author":"N Yao","year":"2016","unstructured":"Yao, N. et al. Multimodal MRI of the hippocampus in Parkinson\u2019s disease with visual hallucinations. Brain Struct. Funct. 221, 287\u2013300 (2016).","journal-title":"Brain Struct. Funct."},{"key":"918_CR135","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.parkreldis.2014.11.020","volume":"21","author":"N Yao","year":"2015","unstructured":"Yao, N. et al. Resting activity in visual and corticostriatal pathways in Parkinson\u2019s disease with hallucinations. Parkinsonism Relat. Disord. 21, 131\u2013137 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"918_CR136","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/mds.26533","volume":"31","author":"JY Lee","year":"2016","unstructured":"Lee, J. Y. et al. Lateral geniculate atrophy in Parkinson\u2019s with visual hallucination: a trans-synaptic degeneration? Mov. Disord. 31, 547\u2013554 (2016).","journal-title":"Mov. Disord."},{"key":"918_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-21847-4","volume":"12","author":"M Miyata","year":"2022","unstructured":"Miyata, M. et al. Optic radiation atrophy in Lewy body disease with visual hallucination on phase difference enhanced magnetic resonance images. Sci. Rep. 12, 18556 (2022).","journal-title":"Sci. Rep."},{"key":"918_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10146-y","volume":"7","author":"DH Hepp","year":"2017","unstructured":"Hepp, D. H. et al. Damaged fiber tracts of the nucleus basalis of Meynert in Parkinson\u2019s disease patients with visual hallucinations. Sci. Rep. 7, 10112 (2017).","journal-title":"Sci. Rep."},{"key":"918_CR139","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1883","volume":"10","author":"N Yuki","year":"2020","unstructured":"Yuki, N., Yoshioka, A., Mizuhara, R. & Kimura, T. Visual hallucinations and inferior longitudinal fasciculus in Parkinson\u2019s disease. Brain Behav. 10, e01883 (2020).","journal-title":"Brain Behav."},{"key":"918_CR140","first-page":"2548","volume":"8","author":"JM Zhong","year":"2013","unstructured":"Zhong, J. M. et al. Why psychosis is frequently associated with Parkinson\u2019s disease? Neural Regen. Res. 8, 2548\u20132556 (2013).","journal-title":"Neural Regen. Res."},{"key":"918_CR141","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1162\/netn_a_00078","volume":"3","author":"JM Hall","year":"2019","unstructured":"Hall, J. M. et al. Changes in structural network topology correlate with severity of hallucinatory behavior in Parkinson\u2019s disease. Netw. Neurosci. 3, 521\u2013538 (2019).","journal-title":"Netw. Neurosci."},{"key":"918_CR142","doi-asserted-by":"publisher","first-page":"726321","DOI":"10.3389\/fnint.2021.726321","volume":"15","author":"K Rootes-Murdy","year":"2022","unstructured":"Rootes-Murdy, K., Goldsmith, D. R. & Turner, J. A. Clinical and structural differences in delusions across diagnoses: a systematic review. Front. Integr. Neurosci. 15, 726321 (2022).","journal-title":"Front. Integr. Neurosci."},{"key":"918_CR143","first-page":"115","volume":"65","author":"SA Factor","year":"1995","unstructured":"Factor, S. A., Molho, E. S., Podskalny, G. D. & Brown, D. Parkinson\u2019s disease: drug-induced psychiatric states. Adv. Neurol. 65, 115\u2013138 (1995).","journal-title":"Adv. Neurol."},{"key":"918_CR144","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1176\/ajp.139.4.494","volume":"139","author":"C Goetz","year":"1982","unstructured":"Goetz, C., Tanner, C. & Klawans, H. Pharmacology of hallucinations induced by long-term drug therapy. Am. J. Psychiatry 139, 494\u2013497 (1982).","journal-title":"Am. J. Psychiatry"},{"key":"918_CR145","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.0000000000000801","volume":"83","author":"P de la Riva","year":"2014","unstructured":"de la Riva, P., Smith, K., Xie, S. X. & Weintraub, D. Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology 83, 1096\u20131103 (2014).","journal-title":"Neurology"},{"key":"918_CR146","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","volume":"132","author":"J Neumann","year":"2009","unstructured":"Neumann, J. et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease. Brain 132, 1783\u20131794 (2009).","journal-title":"Brain"},{"key":"918_CR147","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.parkreldis.2008.11.013","volume":"15","author":"CL Dotchin","year":"2009","unstructured":"Dotchin, C. L., Jusabani, A. & Walker, R. W. Non-motor symptoms in a prevalent population with Parkinson\u2019s disease in Tanzania. Parkinsonism Relat. Disord. 15, 457\u2013460 (2009).","journal-title":"Parkinsonism Relat. Disord."},{"key":"918_CR148","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1212\/WNL.52.1.10","volume":"52","author":"EC Wolters","year":"1999","unstructured":"Wolters, E. C. Dopaminomimetic psychosis in Parkinson\u2019s disease patients: diagnosis and treatment. Neurology 52, S10\u2013S13 (1999).","journal-title":"Neurology"},{"key":"918_CR149","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.biopsych.2018.09.010","volume":"85","author":"RA McCutcheon","year":"2019","unstructured":"McCutcheon, R. A. et al. Mesolimbic dopamine function is related to salience network connectivity: an integrative positron emission tomography and magnetic resonance study. Biol. Psychiatry 85, 368\u2013378 (2019).","journal-title":"Biol. Psychiatry"},{"key":"918_CR150","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.3389\/fphar.2019.01379","volume":"10","author":"M Russo","year":"2019","unstructured":"Russo, M. et al. The pharmacology of visual hallucinations in synucleinopathies. Front. Pharmacol. 10, 1379 (2019).","journal-title":"Front. Pharmacol."},{"key":"918_CR151","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/mds.28913","volume":"37","author":"S van der Zee","year":"2022","unstructured":"van der Zee, S. et al. Altered cholinergic innervation in de novo Parkinson\u2019s disease with and without cognitive impairment. Mov. Disord. 37, 713\u2013723 (2022).","journal-title":"Mov. Disord."},{"key":"918_CR152","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1474-4422(21)00377-X","volume":"21","author":"NI Bohnen","year":"2022","unstructured":"Bohnen, N. I. et al. Cholinergic system changes in Parkinson\u2019s disease: emerging therapeutic approaches. Lancet Neurol. 21, 381\u2013392 (2022).","journal-title":"Lancet Neurol."},{"key":"918_CR153","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ana.410130304","volume":"13","author":"PJ Whitehouse","year":"1983","unstructured":"Whitehouse, P. J., Hedreen, J. C., White, C. L. & Price, D. L. Basal forebrain neurons in the dementia of Parkinson disease. Ann. Neurol. 13, 243\u2013248 (1983).","journal-title":"Ann. Neurol."},{"key":"918_CR154","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/jnnp.48.5.413","volume":"48","author":"EK Perry","year":"1985","unstructured":"Perry, E. K. et al. Cholinergic correlates of cognitive impairment in Parkinson\u2019s disease: comparisons with Alzheimer\u2019s disease. J. Neurol. Neurosurg. Psychiatry 48, 413\u2013421 (1985).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"918_CR155","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1212\/WNL.0b013e3181ab2b58","volume":"73","author":"H Shimada","year":"2009","unstructured":"Shimada, H. et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73, 273\u2013278 (2009).","journal-title":"Neurology"},{"key":"918_CR156","doi-asserted-by":"publisher","first-page":"fcac320","DOI":"10.1093\/braincomms\/fcac320","volume":"4","author":"NI Bohnen","year":"2022","unstructured":"Bohnen, N. I. et al. Progression of regional cortical cholinergic denervation in Parkinson\u2019s disease. Brain Commun. 4, fcac320 (2022).","journal-title":"Brain Commun."},{"key":"918_CR157","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/ana.26596","volume":"93","author":"NJ Ray","year":"2023","unstructured":"Ray, N. J., Kanel, P. & Bohnen, N. I. Atrophy of the cholinergic basal forebrain can detect presynaptic cholinergic loss in Parkinson\u2019s disease. Ann. Neurol. 93, 991\u2013998 (2023).","journal-title":"Ann. Neurol."},{"key":"918_CR158","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1093\/brain\/awp166","volume":"132","author":"F Manganelli","year":"2009","unstructured":"Manganelli, F. et al. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson\u2019s disease. Brain 132, 2350\u20132355 (2009).","journal-title":"Brain"},{"key":"918_CR159","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","volume":"197","author":"MW Johnson","year":"2019","unstructured":"Johnson, M. W., Hendricks, P. S., Barrett, F. S. & Griffiths, R. R. Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol. Ther. 197, 83\u2013102 (2019).","journal-title":"Pharmacol. Ther."},{"key":"918_CR160","first-page":"240","volume":"8","author":"A Hofmann","year":"1959","unstructured":"Hofmann, A. Psychotomimetic drugs; chemical and pharmacological aspects. Acta Physiol. Pharmacol. Neerl. 8, 240\u2013258 (1959).","journal-title":"Acta Physiol. Pharmacol. Neerl."},{"key":"918_CR161","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/0022-510X(91)90193-B","volume":"106","author":"AVT Cheng","year":"1991","unstructured":"Cheng, A. V. T. et al. Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer\u2019s and Parkinson\u2019s diseases. J. Neurol. Sci. 106, 50\u201355 (1991).","journal-title":"J. Neurol. Sci."},{"key":"918_CR162","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1749-6632.1998.tb10229.x","volume":"861","author":"C Chen","year":"1998","unstructured":"Chen, C. et al. Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson\u2019s disease neocortex. Ann. N. Y. Acad. Sci. 861, 288\u2013289 (1998).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"918_CR163","first-page":"3682936","volume":"2016","author":"NB Rasmussen","year":"2016","unstructured":"Rasmussen, N. B. et al. 5-HT2A receptor binding in the frontal cortex of Parkinson\u2019s disease patients and alpha-synuclein overexpressing mice: a postmortem study. Parkinsons Dis. 2016, 3682936 (2016).","journal-title":"Parkinsons Dis."},{"key":"918_CR164","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/mds.23083","volume":"25","author":"P Huot","year":"2010","unstructured":"Huot, P. et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov. Disord. 25, 1399\u20131408 (2010).","journal-title":"Mov. Disord."},{"key":"918_CR165","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1001\/archneurol.2010.35","volume":"67","author":"B Ballanger","year":"2010","unstructured":"Ballanger, B. et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch. Neurol. 67, 416\u2013421 (2010).","journal-title":"Arch. Neurol."},{"key":"918_CR166","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40263-021-00836-7","volume":"35","author":"ES Burstein","year":"2021","unstructured":"Burstein, E. S. Relevance of 5-HT2A receptor modulation of pyramidal cell excitability for dementia-related psychosis: implications for pharmacotherapy. CNS Drugs 35, 727\u2013741 (2021).","journal-title":"CNS Drugs"},{"key":"918_CR167","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1176\/jnp.2006.18.2.149","volume":"18","author":"S Papapetropoulos","year":"2006","unstructured":"Papapetropoulos, S. Regional alpha-synuclein aggregation, dopaminergic dysregulation, and the development of drug-related visual hallucinations in Parkinson\u2019s disease. J. Neuropsychiatry Clin. Neurosci. 18, 149\u2013157 (2006).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"918_CR168","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.neuropharm.2008.08.003","volume":"56","author":"NM Barnes","year":"2009","unstructured":"Barnes, N. M., Hales, T. G., Lummis, S. C. R. & Peters, J. A. The 5-HT3 receptor \u2014 the relationship between structure and function. Neuropharmacology 56, 273\u2013284 (2009).","journal-title":"Neuropharmacology"},{"key":"918_CR169","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41386-021-01255-4","volume":"47","author":"E Tsitsipa","year":"2022","unstructured":"Tsitsipa, E. et al. Selective 5HT3 antagonists and sensory processing: a systematic review. Neuropsychopharmacology 47, 880\u2013890 (2022).","journal-title":"Neuropsychopharmacology"},{"key":"918_CR170","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.schres.2006.07.010","volume":"88","author":"Z-J Zhang","year":"2006","unstructured":"Zhang, Z.-J. et al. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr. Res. 88, 102\u2013110 (2006).","journal-title":"Schizophr. Res."},{"key":"918_CR171","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0197-4580(96)00162-5","volume":"18","author":"AFT Arnsten","year":"1997","unstructured":"Arnsten, A. F. T., Lin, C. H., Van Dyck, C. H. & Stanhope, K. J. The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys. Neurobiol. Aging 18, 21\u201328 (1997).","journal-title":"Neurobiol. Aging"},{"key":"918_CR172","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.neuropharm.2004.03.014","volume":"47","author":"FJ Gil-Bea","year":"2004","unstructured":"Gil-Bea, F. J. et al. Facilitation of cholinergic transmission by combined treatment of ondansetron with flumazenil after cortical cholinergic deafferentation. Neuropharmacology 47, 225\u2013232 (2004).","journal-title":"Neuropharmacology"},{"key":"918_CR173","doi-asserted-by":"publisher","first-page":"110096","DOI":"10.1016\/j.pnpbp.2020.110096","volume":"106","author":"R Garani","year":"2021","unstructured":"Garani, R., Watts, J. J. & Mizrahi, R. Endocannabinoid system in psychotic and mood disorders, a review of human studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 106, 110096 (2021).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"918_CR174","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","volume":"79","author":"H-C Lu","year":"2016","unstructured":"Lu, H.-C. & Mackie, K. An introduction to the endogenous cannabinoid system. Biol. Psychiatry 79, 516\u2013525 (2016).","journal-title":"Biol. Psychiatry"},{"key":"918_CR175","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/nm.f.1869","volume":"14","author":"I Katona","year":"2008","unstructured":"Katona, I. & Freund, T. F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med. 14, 923\u2013930 (2008).","journal-title":"Nat. Med."},{"key":"918_CR176","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fnbeh.2011.00063","volume":"5","author":"E Marco","year":"2011","unstructured":"Marco, E. Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front. Behav. Neurosci. 5, 63 (2011).","journal-title":"Front. Behav. Neurosci."},{"key":"918_CR177","doi-asserted-by":"publisher","first-page":"620.e1","DOI":"10.1016\/j.neurobiolaging.2011.02.009","volume":"33","author":"K Van Laere","year":"2012","unstructured":"Van Laere, K. et al. Regional changes in type 1 cannabinoid receptor availability in Parkinson\u2019s disease in vivo. Neurobiol. Aging 33, 620.e1\u2013620.e8 (2012).","journal-title":"Neurobiol. Aging"},{"key":"918_CR178","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.tins.2022.10.010","volume":"46","author":"EF Halff","year":"2023","unstructured":"Halff, E. F., Rutigliano, G., Garcia-Hidalgo, A. & Howes, O. D. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends Neurosci. 46, 60\u201374 (2023).","journal-title":"Trends Neurosci."},{"key":"918_CR179","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mdc3.12851","volume":"7","author":"S Dave","year":"2020","unstructured":"Dave, S., Weintraub, D., Aarsland, D. & ffytche, D. H. Drug and disease effects in Parkinson\u2019s psychosis: revisiting the role of dopamine. Mov. Disord. Clin. Pract. 7, 32\u201336 (2020).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"918_CR180","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D","volume":"15","author":"JH Friedman","year":"2000","unstructured":"Friedman, J. H. & Factor, S. A. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson\u2019s disease. Mov. Disord. 15, 201\u2013211 (2000).","journal-title":"Mov. Disord."},{"key":"918_CR181","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S0140-6736(94)92511-9","volume":"343","author":"G Meco","year":"1994","unstructured":"Meco, G., Alessandria, A., Bonifati, V. & Giustini, P. Risperidone for hallucinations in levodopa-treated Parkinson\u2019s disease patients. Lancet 343, 1370\u20131371 (1994).","journal-title":"Lancet"},{"key":"918_CR182","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1212\/WNL.55.6.789","volume":"55","author":"CG Goetz","year":"2000","unstructured":"Goetz, C. G., Blasucci, L. M., Leurgans, S. & Pappert, E. J. Olanzapine and clozapine. Neurology 55, 789\u2013794 (2000).","journal-title":"Neurology"},{"key":"918_CR183","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/npr2.12235","volume":"42","author":"K Kashihara","year":"2022","unstructured":"Kashihara, K., Maeda, T. & Yoshida, K. Safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson\u2019s disease\u2014results of a multicenter open trial. Neuropsychopharmacol. Rep. 42, 135\u2013141 (2022).","journal-title":"Neuropsychopharmacol. Rep."},{"key":"918_CR184","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/JPD-181448","volume":"9","author":"JR Younce","year":"2019","unstructured":"Younce, J. R., Davis, A. A. & Black, K. J. A systematic review and case series of ziprasidone for psychosis in Parkinson\u2019s disease. J. Parkinsons Dis. 9, 63\u201371 (2019).","journal-title":"J. Parkinsons Dis."},{"key":"918_CR185","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi, K. et al. Update on treatments for nonmotor symptoms of Parkinson\u2019s disease\u2014an evidence\u2010based medicine review. Mov. Disord. 34, 180\u2013198 (2019).","journal-title":"Mov. Disord."},{"key":"918_CR186","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jamaneurol.2016.0031","volume":"73","author":"D Weintraub","year":"2016","unstructured":"Weintraub, D. et al. Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol. 73, 535\u2013541 (2016).","journal-title":"JAMA Neurol."},{"key":"918_CR187","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","volume":"75","author":"P Pollak","year":"2004","unstructured":"Pollak, P. et al. Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up. J. Neurol. Neurosurg. Psychiatry 75, 689\u2013695 (2004).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"918_CR188","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"Parkinson Study Group.","year":"1999","unstructured":"Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N. Engl. J. Med. 340, 757\u2013763 (1999).","journal-title":"N. Engl. J. Med."},{"key":"918_CR189","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa041470","volume":"351","author":"M Emre","year":"2004","unstructured":"Emre, M. et al. Rivastigmine for dementia associated with Parkinson\u2019s disease. N. Engl. J. Med. 351, 2509\u20132518 (2004).","journal-title":"N. Engl. J. Med."},{"key":"918_CR190","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/mds.21077","volume":"21","author":"D Burn","year":"2006","unstructured":"Burn, D. et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated wsith Parkinson\u2019s disease. Mov. Disord. 21, 1899\u20131907 (2006).","journal-title":"Mov. Disord."},{"key":"918_CR191","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/mds.1204","volume":"16","author":"PJ Reading","year":"2001","unstructured":"Reading, P. J., Luce, A. K. & McKeith, I. G. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov. Disord. 16, 1171\u20131174 (2001).","journal-title":"Mov. Disord."},{"key":"918_CR192","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1474-4422(15)00389-0","volume":"15","author":"EJ Henderson","year":"2016","unstructured":"Henderson, E. J. et al. Rivastigmine for gait stability in patients with Parkinson\u2019s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 15, 249\u2013258 (2016).","journal-title":"Lancet Neurol."},{"key":"918_CR193","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/jamaneurol.2023.1835","volume":"80","author":"E d\u2019Angremont","year":"2023","unstructured":"d\u2019Angremont, E., Begemann, M. J. H., van Laar, T. & Sommer, I. E. C. Cholinesterase inhibitors for treatment of psychotic symptoms in Alzheimer disease and Parkinson disease. JAMA Neurol. 80, 813\u2013823 (2023).","journal-title":"JAMA Neurol."},{"key":"918_CR194","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1124\/jpet.105.097006","volume":"317","author":"KE Vanover","year":"2006","unstructured":"Vanover, K. E. et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine-2A receptor inverse agonist. J. Pharmacol. Exp. Ther. 317, 910\u2013918 (2006).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"918_CR195","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings, J. et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383, 533\u2013540 (2014).","journal-title":"Lancet"},{"key":"918_CR196","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/npp.2009.176","volume":"35","author":"HY Meltzer","year":"2010","unstructured":"Meltzer, H. Y. et al. Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson\u2019s disease psychosis. Neuropsychopharmacology 35, 881\u2013892 (2010).","journal-title":"Neuropsychopharmacology"},{"key":"918_CR197","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa2034634","volume":"385","author":"PN Tariot","year":"2021","unstructured":"Tariot, P. N. et al. Trial of pimavanserin in dementia-related psychosis. N. Engl. J. Med. 385, 309\u2013319 (2021).","journal-title":"N. Engl. J. Med."},{"key":"918_CR198","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.parkreldis.2021.04.012","volume":"87","author":"SH Isaacson","year":"2021","unstructured":"Isaacson, S. H. et al. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson\u2019s disease psychosis patients. Parkinsonism Relat. Disord. 87, 25\u201331 (2021).","journal-title":"Parkinsonism Relat. Disord."},{"key":"918_CR199","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.parkreldis.2020.06.026","volume":"77","author":"CG Ballard","year":"2020","unstructured":"Ballard, C. G. et al. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson\u2019s disease psychosis. Parkinsonism Relat. Disord. 77, 100\u2013106 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"918_CR200","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278262","volume":"18","author":"K Longardner","year":"2023","unstructured":"Longardner, K. et al. Assessing the risks of treatment in Parkinson disease psychosis: an in-depth analysis. PLoS ONE 18, e0278262 (2023).","journal-title":"PLoS ONE"},{"key":"918_CR201","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2022.08.013","volume":"103","author":"TP Pham Nguyen","year":"2022","unstructured":"Pham Nguyen, T. P., Thibault, D., Hamedani, A. G., Weintraub, D. & Willis, A. W. Atypical antipsychotic use and mortality risk in Parkinson disease. Parkinsonism Relat. Disord. 103, 17\u201322 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"key":"918_CR202","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.brainres.2009.08.075","volume":"1300","author":"KM Wildeboer","year":"2009","unstructured":"Wildeboer, K. M., Zheng, L., Choo, K. S. & Stevens, K. E. Ondansetron results in improved auditory gating in DBA\/2 mice through a cholinergic mechanism. Brain Res. 1300, 41\u201350 (2009).","journal-title":"Brain Res."},{"key":"918_CR203","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00213-005-0142-0","volume":"183","author":"K Hashimoto","year":"2005","unstructured":"Hashimoto, K., Iyo, M., Freedman, R. & Stevens, K. E. Tropisetron improves deficient inhibitory auditory processing in DBA\/2 mice: role of \u03b17 nicotinic acetylcholine receptors. Psychopharmacology 183, 13\u201319 (2005).","journal-title":"Psychopharmacology"},{"key":"918_CR204","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12017-013-8251-0","volume":"16","author":"T Kishi","year":"2014","unstructured":"Kishi, T., Mukai, T., Matsuda, Y. & Iwata, N. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review. Neuromolecular Med. 16, 61\u201369 (2014).","journal-title":"Neuromolecular Med."},{"key":"918_CR205","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1212\/WNL.45.7.1305","volume":"45","author":"J Zoldan","year":"1995","unstructured":"Zoldan, J., Friedberg, G., Livneh, M. & Melamed, E. Psychosis in advanced Parkinson\u2019s disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 45, 1305\u20131308 (1995).","journal-title":"Neurology"},{"key":"918_CR206","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/0140-6736(93)90327-D","volume":"341","author":"J Zoldan","year":"1993","unstructured":"Zoldan, J., Friedberg, G., Goldberg-Stern, H. & Melamed, E. Ondansetron for hallucinosis in advanced Parkinson\u2019s disease. Lancet 341, 562\u2013563 (1993).","journal-title":"Lancet"},{"key":"918_CR207","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mds.26142","volume":"30","author":"B Kluger","year":"2015","unstructured":"Kluger, B., Triolo, P., Jones, W. & Jankovic, J. The therapeutic potential of cannabinoids for movement disorders. Mov. Disord. 30, 313\u2013327 (2015).","journal-title":"Mov. Disord."},{"key":"918_CR208","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/WNF.0000000000000246","volume":"40","author":"Y Balash","year":"2017","unstructured":"Balash, Y. et al. Medical cannabis in Parkinson disease: real-life patients\u2019 experience. Clin. Neuropharmacol. 40, 268\u2013272 (2017).","journal-title":"Clin. Neuropharmacol."},{"key":"918_CR209","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00213-021-05905-9","volume":"239","author":"E Chesney","year":"2022","unstructured":"Chesney, E., Oliver, D. & McGuire, P. Cannabidiol (CBD) as a novel treatment in the early phases of psychosis. Psychopharmacology 239, 1179\u20131190 (2022).","journal-title":"Psychopharmacology"},{"key":"918_CR210","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire, P. et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am. J. Psychiatry 175, 225\u2013231 (2018).","journal-title":"Am. J. Psychiatry"},{"key":"918_CR211","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0269881108096519","volume":"23","author":"A Zuardi","year":"2009","unstructured":"Zuardi, A. et al. Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease. J. Psychopharmacol. 23, 979\u2013983 (2009).","journal-title":"J. Psychopharmacol."},{"key":"918_CR212","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","volume":"28","author":"MHN Chagas","year":"2014","unstructured":"Chagas, M. H. N. et al. Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial. J. Psychopharmacol. 28, 1088\u20131098 (2014).","journal-title":"J. Psychopharmacol."},{"key":"918_CR213","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","volume":"382","author":"KS Koblan","year":"2020","unstructured":"Koblan, K. S. et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N. Engl. J. Med. 382, 1497\u20131506 (2020).","journal-title":"N. Engl. J. Med."},{"key":"918_CR214","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/14740338.2022.2069240","volume":"21","author":"SH Isaacson","year":"2022","unstructured":"Isaacson, S. H. & Citrome, L. Hallucinations and delusions associated with Parkinson\u2019s disease psychosis: safety of current treatments and future directions. Expert Opin. Drug Saf. 21, 873\u2013879 (2022).","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00918-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00918-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00918-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T09:10:38Z","timestamp":1709543438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00918-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":214,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["918"],"URL":"https:\/\/doi.org\/10.1038\/s41582-023-00918-8","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"assertion":[{"value":"13 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}